Katherine R Calvo

List of Publications by Year
in descending order

158 papers	11,793 citations	34016 52 h-index	29081 104 g-index
160 all docs	160 docs citations	160 times ranked	14653 citing authors

#	Article	IF	Citations
1	miR-181c regulates MCL1 and cell survival in GATA2 deficient cells. Journal of Leukocyte Biology, 2022, 111, 805-816.	1.5	3
2	Donor source and postâ€transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency. British Journal of Haematology, 2022, 196, 169-178.	1.2	18
3	ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome. Blood Advances, 2022, 6, 793-807.	2.5	24
4	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. , 2022, 10, e003392.		34
5	Skin in the game: theÂemergence of myelodysplasia cutis. Blood, 2022, 139, 1132-1134.	0.6	8
6	Longâ€term eltrombopag for bone marrow failure depletes iron. American Journal of Hematology, 2022, 97, 791-801.	2.0	8
7	Treating Rosaiâ€“Dorfman disease and RASâ€associated autoimmune leucoproliferative disorder with malignant transformation. British Journal of Haematology, 2021, 192, 667-671.	1.2	2
8	An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight, 2021, 6, .	2.3	269
9	Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clinical Cancer Research, 2021, 27, 3298-3306.	3.2	15
10	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. Oncologist, 2021, 26, 288-e541.	1.9	10
11	SASH3variants cause a novel form of X-linked combined immunodeficiency with immune dysregulation. Blood, 2021, 138, 1019-1033.	0.6	28
12	Hematopoietic Cell Transplantation and Outcomes Related to Human Papillomavirus Disease in GATA2 Deficiency. Transplantation and Cellular Therapy, 2021, 27, 435.e1-435.e11.	0.6	9
13	Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. Journal of Clinical Oncology, 2021, 39, 7036-7036.	0.8	0
14	Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis. Blood Cancer Discovery, 2021, 2, 319-325.	2.6	24
15	Distinguishing constitutional from acquired bone marrow failure in the hematology clinic. Best Practice and Research in Clinical Haematology, 2021, 34, 101275.	0.7	11
16	Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Advances, 2021, 5, 3203-3215.	2.5	114
17	Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis and Rheumatology, 2021, 73, 1886-1895.	2.9	125
18	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. JAMA Oncology, 2021, 7, 1678.	3.4	12

#	Article	IF	Citations
19	Association of unbalanced translocation der(1;7) with germline GATA2 mutations. Blood, 2021, 138, 2441-2445.	0.6	12
20	Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia. Pediatric Blood and Cancer, 2021, 68, e28865.	0.8	5
21	Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Advances, 2021, 5, 4807-4816.	2.5	13
22	Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome. Seminars in Hematology, 2021, 58, 204-211.	1.8	27
23	Prospective Phase I/II Study of Eltrombopag for the Treatment of Bone Marrow Failure in Fanconi Anemia. Blood, 2021, 138, 2177-2177.	0.6	0
24	The Spectrum of the Deficiency of Adenosine Deaminase 2: An Observational Analysis of a 60 Patient Cohort. Frontiers in Immunology, 2021, 12, 811473.	2.2	37
25	Differential processing of highâ€molecularâ€weight kininogen during normal pregnancy. Rapid Communications in Mass Spectrometry, 2020, 34, e8552.	0.7	1
26	Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. , 2020, 8, e001563.		22
27	Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features. Leukemia and Lymphoma, 2020, 61, 3177-3187.	0.6	9
28	Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. New England Journal of Medicine, 2020, 383, 2628-2638.	13.9	580
29	Constructing and deconstructing GATA2-regulated cell fate programs to establish developmental trajectories. Journal of Experimental Medicine, 2020, 217, .	4.2	28
30	Myelodysplasia in the setting of paroxysmal nocturnal hemoglobinuria: Interpretation of blast percentage in a marrow with erythroid hyperplasia. EJHaem, 2020, 1, 404-405.	0.4	2
31	Sequencing of RNA in single cells reveals a distinct transcriptome signature of hematopoiesis in GATA2 deficiency. Blood Advances, 2020, 4, 2702-2716.	2.5	23
32	Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2020, 38, 1527-1538.	0.8	58
33	Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report. Pediatric Transplantation, 2020, 24, e13653.	0.5	5
34	Predisposition to hematologic malignancies in patients with xeroderma pigmentosum. Haematologica, 2020, 105, e144-e146.	1.7	18
35	Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Advances, 2020, 4, 1700-1710.	2.5	33
36	Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2020, 83, 269-278.	1.1	4

#	Article	IF	Citations
37	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. Journal of Clinical Investigation, 2020, 130, 1669-1682.	3.9	142
38	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. Blood, 2020, 136, 43-45.	0.6	10
39	Myelodysplasia and Bone Marrow Manifestations of Somatic UBA1 Mutated Autoinflammatory Disease. Blood, 2020, 136, 20-21.	0.6	17
40	Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome. Haematologica, 2020, 105, 2785-2794.	1.7	41
41	Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with GATA 2 Deficiency: Influence of Donor Stem Cell Source and Post-Transplantation Cyclophosphamide. Blood, 2020, 136, 37-38.	0.6	0
42	Somatic Mutations in a Single Residue of UBA1 Cause Vexas, a Severe Adult-Onset Rheumatic Disease Associated with Myeloid Dysplasia. Blood, 2020, 136, 36-37.	0.6	1
43	Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron. Blood, 2020, 136, 39-40.	0.6	0
44	Advances in diagnostic hematopathology. Seminars in Hematology, 2019, 56, 1.	1.8	2
45	Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspiratesâ˜†. Seminars in Hematology, 2019, 56, 65-68.	1.8	3
46	Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications. Seminars in Hematology, 2019, 56, 69-82.	1.8	45
47	Germline Predisposition to Hematolymphoid Neoplasia. American Journal of Clinical Pathology, 2019, 152, 258-276.	0.4	23
48	Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation. Leukemia Research Reports, 2019, 12, 100176.	0.2	11
49	Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia. International Journal of Laboratory Hematology, 2019, 41, 131-141.	0.7	52
50	Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood, 2019, 133, 2575-2585.	0.6	77
51	Hairy cell leukemia coexistent with chronic lymphocytic leukemia. Blood, 2019, 133, 1264-1264.	0.6	4
52	Persistence of skewed X-chromosome inactivation in pre-B acute lymphoblastic leukemia of a female ATRX mutation carrier. Blood Advances, 2019, 3, 2627-2631.	2.5	2
53	Plerixafor for the Treatment of WHIM Syndrome. New England Journal of Medicine, 2019, 380, 163-170.	13.9	74
54	The challenging task of enumerating blasts in the bone marrow. Seminars in Hematology, 2019, 56, 58-64.	1.8	21

#	Article	IF	Citations
55	MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations. Leukemia Research, 2019, 76, 70-75.	0.4	33
56	The distribution of Tâ€cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer, 2019, 125, 1470-1481.	2.0	229
57	Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. Blood, 2019, 134, 1536-1536.	0.6	1
58	Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.. Journal of Clinical Oncology, 2019, 37, 7003-7003.	0.8	5
59	Single-Cell RNA Sequencing Reveals a Distinct Transcriptome Signature of Hematopoiesis in GATA2 Deficiency. Blood, 2019, 134, 3735-3735.	0.6	0
60	GATA2-Dependent Developmental and Regenerative Networks. Blood, 2019, 134, 1182-1182.	0.6	0
61	Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen. Biology of Blood and Marrow Transplantation, 2018, 24, 1250-1259.	2.0	71
62	Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors. Annals of the Rheumatic Diseases, 2018, 77, 612-619.	0.5	49
63	Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Leukemia and Lymphoma, 2018, 59, 178-186.	0.6	2
64	A novel IKAROS haploinsufficiency kindred with unexpectedly late and variable B-cell maturation defects. Journal of Allergy and Clinical Immunology, 2018, 141, 432-435.e7.	1.5	41
65	JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. Journal of Clinical Investigation, 2018, 128, 3041-3052.	3.9	387
66	Donor-derived MDS/AML in families with germline GATA2 mutation. Blood, 2018, 132, 1994-1998.	0.6	48
67	Germline GATA2 Mutation and Bone Marrow Failure. Hematology/Oncology Clinics of North America, 2018, 32, 713-728.	0.9	59
68	Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell, 2018, 173, 1439-1453.e19.	13.5	323
69	Bone Marrow as a Source of Cells for Paroxysmal Nocturnal Hemoglobinuria Detection. American Journal of Clinical Pathology, 2018, 150, 273-282.	0.4	3
70	Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. Journal of Clinical Investigation, 2018, 128, 3071-3087.	3.9	133
71	Adaptive NK cells can persist in patients with GATA2 mutation depleted of stem and progenitor cells. Blood, 2017, 129, 1927-1939.	0.6	89
72	Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. New England Journal of Medicine, 2017, 376, 1540-1550.	13.9	393

#	Article	IF	Citations
73	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Leukemia and Lymphoma, 2017, 58, 639-645.	0.6	11
74	Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD. Journal of Allergy and Clinical Immunology, 2017, 139, 1032-1035.e6.	1.5	62
75	Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight, 2016, 1, .	2.3	219
76	Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation. Journal of Allergy and Clinical Immunology, 2016, 138, 628-630.e2.	1.5	41
77	Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers. Clinical Infectious Diseases, 2016, 63, 41-47.	2.9	56
78	Disruption of in vivo Chronic Lymphocytic Leukemia Tumorâ€“Microenvironment Interactions by Ibrutinib â€“ Findings from an Investigator-Initiated Phase II Study. Clinical Cancer Research, 2016, 22, 1572-1582.	3.2	168
79	Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. New England Journal of Medicine, 2016, 374, 1032-1043.	13.9	217
80	Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. Leukemia and Lymphoma, 2016, 57, 1114-1121.	0.6	23
81	Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. Clinical Cancer Research, 2016, 22, 86-95.	3.2	75
82	GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. Blood, 2015, 125, 56-70.	0.6	131
83	JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood, 2015, 125, 2753-2758.	0.6	94
84	Effect of viral decontamination measures on Wright-stained blood smears. Blood, 2015, 125, 1350-1351.	0.6	3
85	Pediatric myelodysplastic/myeloproliferative neoplasms and related diseases. Journal of Hematopathology, 2015, 8, 159-167.	0.2	4
86	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2015, 1, 746.	3.4	266
87	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 169-176.	5.1	344
88	Bone Marrow Plasma Cells Are a Primary Source of Serum HIV-1â€“Specific Antibodies in Chronically Infected Individuals. Journal of Immunology, 2015, 194, 2561-2568.	0.4	13
89	Chromothriptic Cure of WHIM Syndrome. Cell, 2015, 160, 686-699.	13.5	150
90	Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leukemia and Lymphoma, 2015, 56, 1416-1424.	0.6	23

#	Article	IF	Citations
91	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. Journal of Molecular Diagnostics, 2015, 17, 669-678.	1.2	36
92	Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance. JAMA Oncology, 2015, 1, 1061.	3.4	56
93	Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia, 2014, 28, 413-416.	3.3	24
94	Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leukemia and Lymphoma, 2014, 55, 1402-1403.	0.6	16
95	Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia Research, 2014, 38, 371-376.	0.4	76
96	A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood, 2014, 123, 2308-2316.	0.6	117
97	Glycosylation, Hypogammaglobulinemia, and Resistance to Viral Infections. New England Journal of Medicine, 2014, 370, 1615-1625.	13.9	117
98	GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood, 2014, 123, 809-821.	0.6	599
99	Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood, 2014, 123, 1818-1825.	0.6	336
100	Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency. Biology of Blood and Marrow Transplantation, 2014, 20, 1940-1948.	2.0	84
101	Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. Cytokine, 2014, 69, 294-297.	1.4	15
102	Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine, 2014, 370, 911-920.	13.9	687
103	Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia, 2014, 28, 2188-2196.	3.3	156
104	A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica, 2014, 99, e81-e83.	1.7	112
105	Immunophenotypic profiles of plasma cells and tumor burden in patients with smoldering myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS).. Journal of Clinical Oncology, 2014, 32, e19589-e19589.	0.8	0
106	Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. Leukemia Research, 2013, 37, 401-409.	0.4	100
107	Long-Term Follow-up of Foamy Viral Vector-Mediated Gene Therapy for Canine Leukocyte Adhesion Deficiency. Molecular Therapy, 2013, 21, 964-972.	3.7	35
108	Active thrombopoiesis is associated with worse severity and activity of chronic GVHD. Bone Marrow Transplantation, 2013, 48, 1569-1573.	1.3	9

#	Article	IF	Citations
109	Measurement of the absolute immature platelet number reflects marrow production and is not impacted by platelet transfusion. Transfusion, 2013, 53, 1201-1204.	0.8	32
110	Feasibility and safety of sequential researchâ€related tumor core biopsies in clinical trials. Cancer, 2013, 119, 1357-1364.	2.0	24
111	Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leukemia and Lymphoma, 2013, 54, 2215-2218.	0.6	86
112	Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia. Clinical Cancer Research, 2013, 19, 6873-6881.	3.2	62
113	Plasma Circulating Proteasomes As Biomarkers Along Natural History Of Asymptomatic Monoclonal Gammopathies. Blood, 2013, 122, 3133-3133.	0.6	1
114	Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2013, 122, 538-538.	0.6	30
115	Biologic variations of plasma cells in the bone marrow of smoldering multiple myeloma (SMM) and multiple myeloma (MM) patients: Multiple biopsies in the same patient.. Journal of Clinical Oncology, 2013, 31, e19506-e19506.	0.8	0
116	Altered cytokine profiles in multiple myeloma (MM) and precursor disease: Predictors of progression and potential targets for treatment.. Journal of Clinical Oncology, 2013, 31, 8597-8597.	0.8	0
117	MonoMAC and GATA2 deficiency: overlapping clinical and pathological features with aplastic anemia and idiopathic CD4+ lymphocytopenia. Reply to Haematologica 2012;97(4):058669. Haematologica, 2012, 97, e12-e13.	1.7	8
118	Both variant and IGHV4-34â€“expressing hairy cell leukemia lack the BRAF V600E mutation. Blood, 2012, 119, 3330-3332.	0.6	202
119	Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia. New England Journal of Medicine, 2012, 367, 11-19.	13.9	454
120	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica, 2012, 97, 586-594.	1.7	110
121	Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: Diagnostic and therapeutic challenges. American Journal of Hematology, 2012, 87, 916-922.	2.0	6
122	Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity. Journal of Clinical Investigation, 2012, 122, 3692-3704.	3.9	162
123	Early Myelodysplastic Changes Present in Substantial Proportion of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Patients. Blood, 2012, 120, 1805-1805.	0.6	4
124	Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2012, 120, 732-732.	0.6	7
125	Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.. Journal of Clinical Oncology, 2012, 30, e18568-e18568.	0.8	4
126	A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM).. Journal of Clinical Oncology, 2012, 30, 8088-8088.	0.8	0

#	Article	IF	Citations
127	Role of immune-related conditions in smoldering myeloma and MGUS.. Journal of Clinical Oncology, 2012, 30, 8104-8104.	0.8	2
128	ASXL1 mutations in GATA2-Deficiency Correlate with Leukemic Transformation. Blood, 2012, 120, 405-405.	0.6	0
129	Measurement of the Absolute Immature Platelet Number Reflects Marrow Production and Is Not Impacted by Platelet Transfusion. Blood, 2012, 120, 3425-3425.	0.6	6
130	Clinical Spectrum of RAS-Associated Autoimmune Leukoproliferative Disorder (RALD): A Distinct Clinical Entity Mimicking Juvenile Myelomonocytioc Leukemia (JMML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2012, 120, 1033-1033.	0.6	0
131	Clinically Silent Carriers in Families with Myelodysplastic Syndrome Due to GATA2 Mutations. Blood, 2012, 120, 1264-1264.	0.6	0
132	MCL-1 and Mir-181c in GATA2 Mutation Associated Monomac and Familial Myelodysplastic Syndrome. Blood, 2012, 120, 3807-3807.	0.6	0
133	Peripheral Blood Involvement with Minimal Disease Is Common in Multiple Myeloma but Not in Smoldering Myeloma. Blood, 2012, 120, 4994-4994.	0.6	0
134	Genetic Determinants of the Definitive Hematopoietic Stem/Progenitor Cell Compartment. Blood, 2012, 120, 1226-1226.	0.6	0
135	Altered Plasma Cell Characteristics in Smoldering Myeloma and MGUS Patients with Preceding Immune-Related Conditions. Blood, 2012, 120, 4006-4006.	0.6	4
136	Allogeneic Hematopoietic Stem Cell Transplant Reverses the Phenotype of GATA2 Deficiency.. Blood, 2012, 120, 3091-3091.	0.6	0
137	Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma. Blood, 2012, 120, 570-570.	0.6	0
138	Mastocytosis: the new differential diagnosis of CD30-positive neoplasms. Leukemia and Lymphoma, 2011, 52, 732-733.	0.6	7
139	Flow Cytometry Immunophenotyping of Hematolymphoid Neoplasia. Methods in Molecular Biology, 2011, 699, 295-316.	0.4	20
140	Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood, 2011, 118, 2653-2655.	0.6	572
141	Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood, 2011, 118, 3715-3720.	0.6	131
142	Role of MicroRNAs From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. Seminars in Hematology, 2011, 48, 39-45.	1.8	16
143	Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica, 2011, 96, 1221-1225.	1.7	97
144	Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2. Clinical Cancer Research, 2010, 16, 664-672.	3.2	83

#	Article	IF	Citations
145	Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer. Clinical Cancer Research, 2009, 15, 2361-2372.	3.2	55
146	IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood, 2008, 112, 3818-3826.	0.6	51
147	Primary diffuse large B-cell lymphoma of the spleen with coincident serous retinal detachments responsive to corticosteroids. Clinical and Experimental Ophthalmology, 2007, 35, 468-472.	1.3	7
148	IL-4 Expression and Constitutive Activation of Erk Signaling In Vivo in Follicular Lymphoma.. Blood, 2007, 110, 687-687.	0.6	0
149	Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nature Methods, 2006, 3, 287-293.	9.0	337
150	Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray. Targeted Oncology, 2006, 1, 151.	1.7	2
151	Cardiac Magnetic Resonance Appearance of Myocarditis Caused by High Dose IL-2: Similarities to Community-Acquired Myocarditis. Journal of Cardiovascular Magnetic Resonance, 2006, 8, 353-360.	1.6	28
152	Clinical Proteomics: From Biomarker Discovery and Cell Signaling Profiles to Individualized Personal Therapy. Bioscience Reports, 2005, 25, 107-125.	1.1	119
153	Molecular Profiling Provides Evidence of Primary Mediastinal Large B-Cell Lymphoma as a Distinct Entity Related to Classic Hodgkin Lymphoma. Advances in Anatomic Pathology, 2004, 11, 227-238.	2.4	71
154	Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene, 2002, 21, 4247-4256.	2.6	105
155	Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: Potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13120-13125.	3.3	85
156	Hoxa9 Immortalizes a Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Promyelocyte Capable of Biphenotypic Differentiation to Neutrophils or Macrophages, Independent of Enforced Meis Expression. Molecular and Cellular Biology, 2000, 20, 3274-3285.	1.1	122
157	An inhibitory switch derepressed by Pbx, Hox, and Meis/Prep1 partners regulates DNA-binding by Pbx1 and E2a-Pbx1 and is dispensable for myeloid immortalization by E2a-Pbx1. Oncogene, 1999, 18, 8033-8043.	2.6	39
158	Meis1 and pKnox1 bind DNA cooperatively with Pbx1 utilizing an interaction surface disrupted in oncoprotein E2a-Pbx1. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 14553-14558.	3.3	184